Omnicell (NASDAQ:OMCL) Price Target Cut to $55.00 by Analysts at Piper Sandler

Key Points

• Analysts at Piper Sandler reduced their price target for Omnicell from $57.00 to $55.00, maintaining an "overweight" rating, indicating a potential upside of 78.40% from the previous closing price.
• Other analysts, including Bank of America and Wells Fargo & Company, have also adjusted their price targets, with consensus sitting at a target of $46.71 and a rating of "Moderate Buy."
• Omnicell's stock opened at $30.83, and the company reported earnings of $0.45 per share for the last quarter, exceeding analysts' expectations.

Omnicell (NASDAQ:OMCL - Get Free Report) had its target price lowered by Piper Sandler from $57.00 to $55.00 in a note issued to investors on Monday, August 11th, MarketBeat Ratings reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's target price would indicate a potential upside of 72.77% from the stock's previous close.

Other research analysts have also recently issued reports about the company. Bank of America lifted their price objective on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Wells Fargo & Company increased their price target on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Finally, Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, Omnicell presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Price Performance

NASDAQ OMCL traded up $0.2250 during midday trading on Monday, hitting $31.8350. The company had a trading volume of 318,541 shares, compared to its average volume of 567,196. The firm has a 50-day moving average price of $29.45 and a 200-day moving average price of $32.07. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.74. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.46 billion, a PE ratio of 63.98, a P/E/G ratio of 9.25 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell's revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, analysts anticipate that Omnicell will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the stock. Liontrust Investment Partners LLP grew its position in shares of Omnicell by 81.2% in the second quarter. Liontrust Investment Partners LLP now owns 318,284 shares of the company's stock valued at $9,358,000 after purchasing an additional 142,629 shares in the last quarter. Public Sector Pension Investment Board raised its holdings in Omnicell by 8.7% during the second quarter. Public Sector Pension Investment Board now owns 159,658 shares of the company's stock valued at $4,694,000 after acquiring an additional 12,742 shares during the period. Headlands Technologies LLC boosted its stake in Omnicell by 1,865.0% during the second quarter. Headlands Technologies LLC now owns 18,137 shares of the company's stock valued at $533,000 after buying an additional 17,214 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in Omnicell by 3.2% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 53,233 shares of the company's stock valued at $1,566,000 after buying an additional 1,638 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock worth $146,000 after purchasing an additional 3,932 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.